Lantern Pharma Announces Significant Positive Preclinical Data in Pancreatic Cancer With Drug Candidate LP-184

• LP-184 is a next-generation DNA-damaging agent being developed for pancreatic cancer in a collaboration with Fox Chase Cancer Center • LP-184 has demonstrated significant potency across a wide range of studies, in-vitro, ex-vivo and in-vivo, and is being positioned for areas of high unmet need in genetically targeted pancreatic cancers • Pancreatic tumors with DNA-damage repair deficiencies were significantly more sensitive, by 2x, to LP-184 • Lantern’s A.I. based identification of the key gene in the drug mechanism-of-action for LP-184 was validated by leveraging gene-editing (CRISPR) technology to validate PTGR1 as a fundamental driver of tumor sensitivity and cancer cell death

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here